New Analysis of Phase 3 Pooled Data for Organon’s VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults¹
Go back to New Analysis of Phase 3 Pooled Data for Organon’s VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults¹| (NYSE: OGN) | Delayed: 13.68 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $13.68 | 52 Week High | $8.00 | |||
| Open | $13.70 | 52 Week Low | $8.00 | |||
| Day High | $13.76 | P/E | N/A | |||
| Day Low | $13.67 | EPS | $0.00 | |||
| Volume | 3,116,460 | |||||
